These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9780193)

  • 1. Weak anamnestic responses of inbred mice to Yersinia F1 genetic vaccine are overcome by boosting with F1 polypeptide while outbred mice remain nonresponsive.
    Brandler P; Saikh KU; Heath D; Friedlander A; Ulrich RG
    J Immunol; 1998 Oct; 161(8):4195-200. PubMed ID: 9780193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of CD8+ T cell responses by Yersinia vaccine carrier strains.
    Wiedig CA; Kramer U; Garbom S; Wolf-Watz H; Autenrieth IB
    Vaccine; 2005 Oct; 23(42):4984-98. PubMed ID: 15985316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses.
    Elvin SJ; Williamson ED
    Microb Pathog; 2000 Oct; 29(4):223-30. PubMed ID: 10993741
    [No Abstract]   [Full Text] [Related]  

  • 5. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.
    Glynn A; Roy CJ; Powell BS; Adamovicz JJ; Freytag LC; Clements JD
    Infect Immun; 2005 Aug; 73(8):5256-61. PubMed ID: 16041052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
    Yang X; Hinnebusch BJ; Trunkle T; Bosio CM; Suo Z; Tighe M; Harmsen A; Becker T; Crist K; Walters N; Avci R; Pascual DW
    J Immunol; 2007 Jan; 178(2):1059-67. PubMed ID: 17202369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
    Tripathi V; Chitralekha KT; Bakshi AR; Tomar D; Deshmukh RA; Baig MA; Rao DN
    Vaccine; 2006 Apr; 24(16):3279-89. PubMed ID: 16476510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
    Jones T; Adamovicz JJ; Cyr SL; Bolt CR; Bellerose N; Pitt LM; Lowell GH; Burt DS
    Vaccine; 2006 Mar; 24(10):1625-32. PubMed ID: 16243411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunisation against plague by transcutaneous and intradermal application of subunit antigens.
    Eyles JE; Elvin SJ; Westwood A; Lebutt CS; Alpar HO; Somavarapu S; Williamson ED
    Vaccine; 2004 Oct; 22(31-32):4365-73. PubMed ID: 15474730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
    Gupta A; Narayan B; Kumar S; Verma SK
    Front Immunol; 2020; 11():988. PubMed ID: 32595634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yersinia enterocolitica Yop mutants as oral live carrier vaccines.
    Leibiger R; Niedung K; Geginat G; Heesemann J; Trülzsch K
    Vaccine; 2008 Dec; 26(51):6664-70. PubMed ID: 18822332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen.
    Garmory HS; Freeman D; Brown KA; Titball RW
    Vaccine; 2004 Feb; 22(8):947-57. PubMed ID: 15161071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the protection efficiency of secretory antibodies in experimental Yersinia infection in guinea-pigs immunized with polyvalent vaccine against this infection].
    Pogorel'skiĭ IP; Drobkov VI
    Patol Fiziol Eksp Ter; 2009; (4):26-8. PubMed ID: 20146406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague.
    Elvin SJ; Williamson ED
    Microb Pathog; 2004 Oct; 37(4):177-84. PubMed ID: 15458778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ecological interactions among Yersinia in their common reservoir, the rodent].
    Alonso JM
    Bull Soc Pathol Exot; 1999 Dec; 92(5 Pt 2):414-7. PubMed ID: 11000952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against Yersinia infection induced by non-virulence-plasmid-encoded antigens.
    Simonet M; Berche P; Mazigh D; Veron M
    J Med Microbiol; 1985 Oct; 20(2):225-31. PubMed ID: 3900406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yersinia pestis F1 antigen: a correlation between antibody titres and subclass distribution with differential avidity in different inbred mouse strains.
    Sabhnani L; Manocha M; Tomar D; Shashikiran D; Rao DN
    Int Immunopharmacol; 2003 Oct; 3(10-11):1413-8. PubMed ID: 12946437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.